Melanoma - Global Drug Forecast and Market Analysis to 2023

1
PharmaPoint Melanoma
Global Drug Forecast and Market Analysis
to 2023
2
Report Description
Summary   Melanoma is the deadliest and most
aggressive form of skin cancer. The major
treatments for melanoma are categorized into
immunotherapies and BRAF mutation-targeted
therapies. GlobalData estimates the 2013 sales
for melanoma at approximately 1.34 billion
across the 8MM covered in this report. The market
will increase by four-fold over the forecast
period, reaching 5.64 billion in 2023 at a CAGR
of 15.5. This growth will be driven by an
increase in melanoma incident cases as well as
the approval and uptake of premium-priced
products, such as PD-1-targeting mAbs and
BRAF/MEK inhibitor combinations. GlobalData
expects, by the end of the forecast period, the
checkpoint immunotherapy drug class to dominate
the melanoma market (including both BRAF
wild-type and mutation-positive patient segments)
with an overall 67 share of the melanoma
market. The melanoma pipeline is strong
however, GlobalData expects none of these drugs
to have a major impact on the overall melanoma
market, as the market is crowded with effective
immunotherapies and BRAF mutation-targeted
agents. Read more details at
http//www.bigmarketresearch.com/pharmapoint-melan
oma-global-drug-forecast-and-analysis-to-2023-mark
et
3
Report Description

• Key Questions Answered
•  
• The melanoma space is filled with the excitement
  of recently approved anti-PD-1 immunotherapies,
  which are expected to revolutionize the treatment
  landscape. What will be the impact of these newly
  approved drugs and their projected label
  expansions on the melanoma sales?
• As the melanoma market is getting increasingly
  crowded with multiple anti-PD-1 immunotherapies
  and BRAF mutation-targeted agents, opportunities
  for new entrants become limited. What RD
  strategies are being used by drug makers to
  remain competitive?
• The survival of patients with metastatic melanoma
  remains short, especially for those
• who do not response to anti-PD-1
  immunotherapies. Therefore, there are
  considerably high unmet needs
  within the indication. What are the main unmet
  needs in this market. Will the drugs under
  development fulfil the unmet needs of the
  melanoma market?
•  

4
Key Findings

• Key Findings
•  
• One of the main drivers of the enormous expansion
  of the gout market will be the launch of
  premium-priced metastatic therapies, such as
  anti-PD-1 immunotherapy and BRAF/MEK inhibitor
  combinations. These drugs will extend treatment
  duration and replace cheaper, generic,
  chemotherapy regimens.
• Another strong driver will be the label extension
  of current therapies into the new settings for
  example, PD-1s will garner label extension for
  the first-line treatment in 2015-16, and the
  metastatic brands are expected to be approved in
  the adjuvant setting in the second half of the
  forecast period.
• Companies are focusing on the development of
  combination immunotherapies, trying to improve
  the response rate and response duration of drugs.
• One of the largest unmet needs is a need for
  efficacious treatment options for BRAF wild-type
  patients. Approximately half of melanoma patients
  do not have BRAF mutations, and are therefore
  non-eligible for BRAF/MEK inhibitor treatments.
  Other unmet needs include therapies for PD-1
  immunotherapy non-responders, adjuvant treatment
  for patients with resected melanoma, effective
  treatment for brain metastasis

5
Scope

• Scope
•  
• Overview of melanoma, including epidemiology,
  etiology, pathophysiology, symptoms, diagnosis,
  and disease management.
• Annualized melanoma therapeutics market revenue,
  cost of therapy per patient, and treatment usage
  patterns in six patient segments (including
  adjuvant, BRAF mutated and BRAF wild-type),
  forecast from 2013 to 2023.
• Key topics covered include strategic competitor
  assessment, market characterization, unmet needs,
  clinical trial mapping and implications for the
  melanoma therapeutics market
• Pipeline analysis comprehensive data assessing
  emerging trends and mechanisms of action under
  development for different lines of therapy. The
  most promising candidate in Phase III development
  is profiled.

6
Reasons to buy

• Reasons to buy
•  
• Develop and design your in-licensing and
  out-licensing strategies through a review of
  pipeline products and technologies, and by
  identifying the companies with the most robust
  pipeline.
• Develop business strategies by understanding the
  trends shaping and driving the global melanoma
  therapeutics market.
• Drive revenues by understanding the key trends,
  innovative products and technologies, market
  segments, and companies likely to impact the
  global melanoma therapeutics market in the
  future.
• Formulate effective sales and marketing
  strategies by understanding the competitive
  landscape and by analysing the performance of
  various competitors.
• About Report http//www.bigmarketresearch.com/rep
  ort-enquiry/308033

7
FOR MORE DETAILS
Visit us at
http//www.bigmarketresearch.com/pharmapoint-melan
oma-global-drug-forecast-and-analysis-to-2023-mark
et
Stay With Us
TELEPHONE [phone] EMAIL
help_at_bigmarketresearch.com
5933 NE Win Sivers Drive,205, Portland, OR
97220United States